Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1

Conditions

Recurrence 1Leukemia, Myeloid, Acute 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 36Cisplatin 32pembrolizumab 29Paclitaxel 29Pemetrexed 22Gemcitabine 21Nivolumab 19Dexamethasone 17Rituximab 16Fluorouracil 13Docetaxel 13Ipilimumab 12Capecitabine 12durvalumab 11Cyclophosphamide 11atezolizumab 10130-nm albumin-bound paclitaxel 10olaparib 9Trastuzumab 9Lenalidomide 9Doxorubicin 9Cytarabine 9Bevacizumab 9daratumumab 8Oxaliplatin 8Bortezomib 8Vinorelbine 7Prednisone 7Leucovorin 7venetoclax 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × Drug Therapy × Clear all
NCT03409614 2026-05-18

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Regeneron Pharmaceuticals

Phase 3 Completed
789 enrolled 32 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03581786 2025-09-02

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Completed
289 enrolled 32 charts 1 FDA

Recurrence

NCT02668653 2024-08-06

QuANTUM-First

Daiichi Sankyo

Phase 3 Completed
539 enrolled 20 charts 1 FDA
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡